Evaluating the cost‐effectiveness of hepatitis B vaccination strategies in high‐impact settings for adults
- 14 October 2022
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 29 (12) , 1115-1126
Abstract
Adults at increased risk for hepatitis B virus (HBV) infection are recommended to receive vaccination. We conducted a cost utility analysis to evaluate approaches for implementing that recommendation in selected high-risk settings: community outreach events with a large proportion of immigrants, syringe service programs, substance use treatment centres, sexually transmitted infection (STI) clinics, tuberculosis (TB) clinics and jails. We utilized a decision tree framework with a Markov disease progression model to compare quality adjusted life-years and cost in 2021 United States dollars from four strategies: a 3-dose vaccination regimen with prevaccination screening and testing (PVST; baseline comparison); PVST at the initial encounter followed by a 2-dose series (Intervention 1); PVST with the first dose of a 2-dose vaccination series at the initial encounter (Intervention 2); and a 2-dose vaccination series without PVST (Intervention 3). In all settings, Intervention 1 resulted in worse health outcomes compared with the baseline strategy. Intervention 2 averted incident chronic HBV infections in all settings (range -9.4% in TB clinics, -14.8% in syringe service programs) and was a cost-saving approach in settings with higher risk of infection (i.e. jails, -$266 per person; syringe service programs, -$597; substance use treatment centres, -$130). Providing a 2-dose vaccination series without any screening (Intervention 3) averted incident HBV infections and was cost-saving in all settings but resulted in more HBV-related deaths in settings with higher HBV prevalence. These results demonstrate a 2-dose vaccine series is a cost-effective approach in these high-impact settings, even if prevaccination testing is not possible.Keywords
Funding Information
- National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention (NU38PS004650)
- Centers for Disease Control and Prevention
- National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention (NU38PS004650)
- Centers for Disease Control and Prevention
This publication has 30 references indexed in Scilit:
- HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014–2015New England Journal of Medicine, 2016
- National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014MMWR. Morbidity and Mortality Weekly Report, 2015
- A Case Study of a Hepatitis B Screening and Blood Pressure Assesment Program in Los Angeles County, 2012–2013Preventing Chronic Disease, 2015
- Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000–2010Epidemiology and Infection, 2014
- Estimating Acute Viral Hepatitis Infections From Nationally Reported CasesAmerican Journal of Public Health, 2014
- Prevalence and Incidence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infections Among Males in Rhode Island PrisonsAmerican Journal of Public Health, 2004
- A 2-Dose Regimen of a Recombinant Hepatitis B Vaccine with the Immune Stimulant AS04 Compared with the Standard 3-Dose Regimen of Engerix-B in Healthy Young AdultsScandinavian Journal of Infectious Diseases, 2002
- A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adultsVaccine, 2001
- Syringe Exchange and Risk of Infection with Hepatitis B and C VirusesAmerican Journal of Epidemiology, 1999
- Immunogenicity of two recombinant hepatitis B vaccines in older individualsThe American Journal of Medicine, 1993